Intrathecal catheter granuloma associated with isolated baclofen infusion.
Intrathecal (IT) baclofen is an effective management strategy for controlling spasticity in patients unresponsive to maximal oral therapy. We present the case of a 57-yr-old woman who was rendered quadriplegic after a complete spinal cord transection at the C6 level. Her course was complicated by severe spasms, which were uncontrolled despite titrating orally administered baclofen to 80 mg/d. IT baclofen testing was performed with good response, and administration was commenced via an implanted intrathecal pump 6 mo after the injury at an initial dose of 200 microg/d. Catheter revision was required 2 wk later as a result of catheter displacement. The initial IT baclofen dose was gradually increased to achieve good control at a level of 400 microg/d. After a period of stability lasting 38 mo, her lower limb spasms dramatically increased in severity and remained poorly controlled despite repeated dose increases. Contrast pumpogram and computed tomography myelogram were performed to exclude a mechanical cause for this apparent increase in baclofen requirement. These investigations revealed neither catheter displacement nor fracture as suspected but, rather, displayed the presence of a catheter tip-associated mass. Catheter tip granuloma has not previously been described in a patient receiving IT baclofen alone. This suggests that although uncommon, the possibility of catheter-associated granuloma must be considered in all patients receiving IT baclofen presenting with altered neurological function or significant increase in drug requirement.
University of Sydney Pain Management and Research Institute, Department of Radiology, Royal North Shore Hospital, St. Leonards, NSW, Australia. drpmurphy@hotmail.com
Paul M
PM
Murphy
Danielle E
DE
Skouvaklis
Ryan J J
RJ
Amadeo
Craig
C
Haberman
David H
DH
Brazier
Michael J
MJ
Cousins
D001418:Baclofen / Q000008:administration & dosage* / Q000009:adverse effects; D002408:Catheters, Indwelling / Q000009:adverse effects; D016503:Drug Delivery Systems / Q000009:adverse effects*; D005260:Female; D006099:Granuloma / Q000175:diagnosis* / Q000517:prevention & control; D006801:Humans; D015918:Infusion Pumps, Implantable / Q000009:adverse effects*; D007278:Injections, Spinal; D008159:Lumbar Vertebrae / Q000187:drug effects; D008875:Middle Aged
D001418:Baclofen